- Innovating macrophage-targeted therapeutics across multiple therapeutic areas
- Proprietary functional macrophage fingerprinting technology identifies disease-relevant macrophage subsets
- Strengthened by the appointments of James Rush as CEO and Jim Van heusden as Chairman
- Powered by Bioqube Ventures’ venture creation model
Spica was founded on groundbreaking research into macrophage biology conducted at the University of Aarhus, Southern Denmark University and INSERM. The company’s foundational work, including novel insights into its lead target, was recently published in Nature Communications.
“We are thrilled to see our scientific foundations evolve into potentially life-changing therapies with Bioqube’s hands-on support,” said Dr. Anders Etzerodt, co-founder and Chief Scientific Officer (CSO).
“Targeting macrophage subsets paves the way for novel therapies across a range of diseases,” added Debbie Dumont, Managing Partner at Bioqube Ventures. “Spica’s impressive progress underscores the strength of our venture creation model.”
Coinciding with the unstealthing, Spica Therapeutics has bolstered its leadership team with the appointment of industry veterans James Rush as CEO and Jim Van heusden as Chairman of the Board. These seasoned professionals bring extensive experience in drug development and executive leadership, positioning Spica for its next phase of development.
“Spica’s approach to modulating macrophages is truly innovative, and I am excited to support this talented team,” said Jim Van heusden.
James Rush added, “Our novel, human disease-based insights into pathogenic macrophage subsets have laid the foundation for two exciting lead programs. With the continued backing of Bioqube, we are well positioned to raise a seed round to advance the platform and move both programs towards clinical trials.”
